Steven B. Kanner,David L. Lewis,Darren H. Wakefield,Lauren J. Almeida
申请号：
US16429501
公开号：
US20190359984A1
申请日:
2019.06.03
申请国别(地区):
US
年份:
2019
代理人:
摘要：
RNA interference (RNAi) triggers for inhibiting the expression of Factor XII (F12) gene through the mechanism of RNA interference are described. Pharmaceutical compositions comprising one or more F12 RNAi triggers together with one or more excipients capable of delivering the RNAi trigger(s) to a liver cell in vivo are also described. Delivery of the F12 RNAi trigger(s) to liver cells in vivo provides for inhibition of F12 gene expression and treatment of angioedema, including hereditary angioedema (HAE) and venous thromboembolism (VTE), and diseases associated with angioedema.
